Enhancing the efficacy of immunity-activating nucleic acid drugs

Enhancing the efficacy of immunity-activating nucleic acid drugs
Change in efficacy of CpG ODN by use of nanoparticles. (Left) Free CpG ODN molecules induce interleukin 6 (IL-6) by interaction with TLR9. (Center) When CpG ODN is electrostatically bound to silicon nanoparticles (blue circles), induction of interferon (IFN) becomes possible. (Right) When bound only to one end of the silicon nanoparticles, CpG ODN induces IL-6 in the same manner as free CpG ODN.

(Phys.org)—The Nanotechnology Innovation Station of the National Institute for Materials Science has succeeded in development of a technology which utilizes nanoparticles to enhance the action of immunity activating nucleic acid drugs.

Nucleic acid drugs—produced by DNA or RNA—are cutting-edge molecular target drugs that target designated proteins or base sequences with pinpoint accuracy. Nucleic acid drugs are anticipated as potential treatment for cancers, , , and allergic diseases such as pollenosis, etc. In the present research, NIMS succeeded in developing a technology which uses nanoparticles to enhance the efficacy of immunity-activating nucleic acid drugs, with the aim of application to pollenosis and similar diseases.

The nucleic drugs called CpG ODN (cytosine-phosphate-guanine oligodeoxynucleotides), which have already been developed, mainly includes two types. One is the interferon type, which primarily induces interferon. The other is the interleukin type, which induces . Interferon and interleukin 6 are substances that are related to immunostimulation. However, with the conventional method, it was not possible to induce interferon and interleukin 6 simultaneously, even when these two types of CpG ODN were administered simultaneously to increase immune effect.

In the present research, only the interleukin type of CpG ODN was used. This CpG ODN was bound to silicon nanoparticles by two different methods, and the two types of nanoparticles were used simultaneously. As a result, the NIMS researchers succeeded in simultaneously activating and interleukin 6 at a high level for the first time.

The method, in which drugs are applied to medical treatment using nanoparticles as a carrier, is called . In the conventional approach, the main role of the nanoparticles in drug delivery was to deliver the drug to the targeted cells or tissue and release the drug at the affected part. In the present research, the role of the nanoparticles is not limited to the drug transportation and release functions. The nanoparticles also play a critical role in enabling control of manifestation of the effect of the drug.

This achievement will make it possible to apply this drug to treatment of infectious diseases, immunotherapy for cancers, and treatment of pollenosis and other . Application of nucleic acid drugs other than CpG ODN can also be expected.

More information: These research results was published in Scientific Reports, an online journal of British Nature Publishing Group.  

Journal information: Scientific Reports

Citation: Enhancing the efficacy of immunity-activating nucleic acid drugs (2012, August 23) retrieved 10 December 2022 from https://phys.org/news/2012-08-efficacy-immunity-activating-nucleic-acid-drugs.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Understanding how cells respond to nanoparticles

0 shares

Feedback to editors